Key result
Rising global demand for infectious disease monoclonal antibodies requires metric ton scale manufacturing expansion.
Why the study?
The unmet need for antibody-based products in infectious diseases and increasing access to existing products will likely exceed current global manufacturing capacity.
There is a critical need to expand global manufacturing infrastructure to metric ton scale to meet the demand for monoclonal antibodies in infectious diseases like COVID-19.
This review focuses on the emerging monoclonal antibody market for infectious diseases and the metric ton scale manufacturing requirements to meet global demand. Increasing access to existing antibody-based products coupled with the unmet need in infectious disease will likely exceed the current existing global manufacturing capacity. Further, the large numbers of individuals infected during epidemics such as the ongoing COVID-19 pandemic emphasizes the need to plan for metric ton manufacturing of monoclonal antibodies by expanding infrastructure and exploring alternative production systems.
No takes yet. Share an insight, caveat, or question.
Whaley et al. (2021) conducted a review in Infectious diseases. Monoclonal antibodies was evaluated. The increasing global demand for monoclonal antibodies for infectious diseases, including COVID-19, necessitates planning for metric ton scale manufacturing and expanding production infrastructure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: